Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Ciprofloxacin dispersion for inhalation
Ciprofloxacin dispersion · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Ciprofloxacin dispersion for inhalation | EXPERIMENTAL | Liquid mixture of liposomally encapsulated and unencapsulated ciprofloxacin |
| Placebo | PLACEBO_COMPARATOR | Liquid formulation of empty liposomes |
| Name | Type | Description |
|---|---|---|
| Ciprofloxacin dispersion for inhalation | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Confirmed diagnosis of non-CF bronchiectasis * History of P. aeruginosa respiratory infections * At least two pulmonary exacerbations treated with antibiotics in the previous year Exclusion Criteria: * Have a clinical diagnosis of CF * Are pregnant
Ciprofloxacin dispersion for inhalation is an investigational inhaled antibiotic being developed for non cystic fibrosis bronchiectasis. It is delivered as a dispersion for inhalation to treat this chronic respiratory condition in adults. It is not approved and remains in clinical development.
Ciprofloxacin dispersion for inhalation is being developed by Grifols, S.A., which trades under the ticker GRFS. Grifols is the sponsor of the Phase 3 clinical program evaluating this inhaled antibiotic in non cystic fibrosis bronchiectasis.
Ciprofloxacin dispersion for inhalation is in Phase 3 development. Two Phase 3 trials have been completed, and no active trials are currently listed. The drug is investigational and has not been approved for commercial use.
Ciprofloxacin dispersion for inhalation has been studied in two completed Phase 3 trials: ORBIT-4 (NCT02104245), which enrolled 304 participants, and ORBIT-3 (NCT01515007), which enrolled 278 participants. Both were randomized, double blind, placebo controlled studies in adults with non cystic fibrosis bronchiectasis.